The aim of this Phase 3 study is to investigate the use of benralizumab as a treatment for patients with Eosinophilic Gastritis and/or Gastroenteritis. The effect of doses of benralizumab on EG/EGE histologic signs and symptoms will be assessed in a 24-week double-blind placebo-controlled treatment period followed by assessments during an open-label benralizumab treatment period. It is proposed that benralizumab will deplete eosinophilis, improve the symptoms in patients with eosinophilic gastritis and/or gastroenteritis, and improve histologic scores as well as other markers of disease activity.
This is a 3-part study. Part A and B have identical designs and are randomized, double-blinded, placebo-controlled studies, which will include patients with eosinophilic gastritis and/or duodenal-only disease. Part A will be enrolled first, followed by Part B. After completing Part A or Part B, participants will continue to Part C - open-label benralizumab treatment period.